Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
independent lines of investigation within the broader research program. The role of Post-Doctoral Fellow will report to Head of the Bull Lab. Some skills required: A PhD in virology, immunology or in a related
-
combatting wildlife trafficking and environmental harm. To be successful you will need: PhD in a relevant discipline such as computer science, data science, digital forensics, cyber security or a related field
-
Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural Director of the Adelaide Centre for Epigenetics (ACE). Together
-
Doctoral Scientist position. This position will report to Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural
-
. degree (up to one year into the future) are also encouraged to apply. PhD awarding university must be ranked in the QS Top 500 (2025 edition ) Essential Knowledge & Skills In-depth knowledge and a strong
-
predictive control, and/or reinforcement learning. PhD (or soon to be completed) in engineering, applied mathematics, or computer science, with an ability to start in mid-late 2025 a research track record
-
PhD in a related area: Mathematics, Computer Science, or Engineering, and have an aptitude and demonstrated capability to publish in top ranked avenues in their field of study. Depending on experience
-
CEPAR’s Asia program. Conduct research independently or as part of a team. Build and use models, software, and databases; analyse data and share findings. Help prepare funding applications with guidance
-
academic, industry, and government partners Participate in team meetings and cross-disciplinary discussions Publish high-quality research in journals and conferences Who You Are: PhD in actuarial studies
-
fundamental research and the pharmaceutical and biotechnology industries. The research program is co-funded by the Australian Research Council and the Sydney- and US-based biotech company INSAMO and the